Current Health News Recap: Key Approvals, Lawsuits, and Market Moves

Astellas Pharma's gastric cancer therapy gets UK approval. Glenmark Pharma reports Q1 profit surge. Texas sues Biden administration over a nursing home staffing rule. J&J prepares talc settlement support announcement. WHO declares mpox a global emergency. FDA approves treatments from Incyte and Gilead Sciences.

Astellas Pharma's new therapy for gastric cancer received approval from the UK's health regulator, combining a monoclonal antibody with standard chemotherapy for adults.

Glenmark Pharmaceuticals reported significant first-quarter profit growth, driven by high demand and reduced costs.

Texas's Attorney General filed a lawsuit against the Biden administration's nursing home staffing rule, citing the nationwide nursing shortage as a compliance issue for many long-term care facilities.

Sources indicate Johnson & Johnson will soon announce substantial support for a $6.48 billion talc settlement, which aims to resolve ongoing legal battles over cancer claims.

The World Health Organization declared mpox a global public health emergency due to an outbreak in the Democratic Republic of Congo that has spread to neighboring regions.

Incyte Corporation's treatment for chronic graft-versus-host disease secured approval from the U.S. FDA for both adult and pediatric patients.

Cardinal Health raised its 2025 profit outlook based on strong demand for specialty medicines, countering declining prices of generic drugs.

Gilead Sciences' new liver disease treatment, Livdelzi, received FDA approval following the company's acquisition of CymaBay Therapeutics.

Montana's Supreme Court overturned a law requiring parental consent for minors seeking abortion, upholding their reproductive rights.

Eli Lilly issued cease-and-desist letters to several U.S. healthcare providers to stop the sale of compounded versions of its weight-loss and diabetes treatments Zepbound and Mounjaro.

(With inputs from agencies.)